Drug Trials Snapshots: VEOZAH (fezolinetant)

VEOZAH is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-veozah